Global Pulmonary Embolism Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Pulmonary Embolism treatment during 2019. Clinical development activities are being undertaken by more than 5 companies including Daiichi Sankyo Co Ltd, Dong-A Socio Holdings, Tasly Pharmaceutical Group Co Ltd, TeaRx Ltd., Verseon Corp and others.
A Significant contribution to the Pulmonary Embolism pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Pulmonary Embolism pipeline included 5 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Pulmonary Embolism condition and increased access to investments is encouraging growth of Pulmonary Embolism drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Pulmonary Embolism drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Pulmonary Embolism therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Pulmonary Embolism pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Pulmonary Embolism. Further, orphan drug status, fast track designation, grants awarded and other special status for Pulmonary Embolism pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Pulmonary Embolism pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Pulmonary Embolism Pipeline candidates-
A Significant contribution to the Pulmonary Embolism pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Pulmonary Embolism pipeline included 5 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Pulmonary Embolism condition and increased access to investments is encouraging growth of Pulmonary Embolism drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Pulmonary Embolism drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Pulmonary Embolism therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Pulmonary Embolism pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Pulmonary Embolism. Further, orphan drug status, fast track designation, grants awarded and other special status for Pulmonary Embolism pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Pulmonary Embolism pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Pulmonary Embolism Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Pulmonary Embolism drugs
- Late phase: Phase 3 and in-approval Pulmonary Embolism drugs
- Company overview
- Snapshot
- Pulmonary Embolism therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Pulmonary Embolism- Disease Overview
2.2 Pulmonary Embolism- Pipeline Snapshot
2.3 Pulmonary Embolism- Pipeline Drugs by Phase
2.4 Pulmonary Embolism- Pipeline Drugs by Company
2.5 Pulmonary Embolism- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Daiichi Sankyo Co Ltd Pulmonary Embolism Drug Pipeline, H2- 2019
3.2 Dong-A Socio Holdings Pulmonary Embolism Drug Pipeline, H2- 2019
3.3 Tasly Pharmaceutical Group Co Ltd Pulmonary Embolism Drug Pipeline, H2- 2019
3.4 TeaRx Ltd. Pulmonary Embolism Drug Pipeline, H2- 2019
3.5 Verseon Corp Pulmonary Embolism Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Pulmonary Embolism- Phase 1 Drug Details
4.2 Pulmonary Embolism- Phase 1 Drug Overview
4.3 Pulmonary Embolism- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Pulmonary Embolism- Phase 2 Drug Details
5.2 Pulmonary Embolism- Phase 2 Drug Overview
5.3 Pulmonary Embolism- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Pulmonary Embolism- Phase 3 Drug Details
6.2 Pulmonary Embolism- Phase 3 Drug Overview
6.3 Pulmonary Embolism- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Pulmonary Embolism- Pre-clinical Phase Drug Details
7.2 Pulmonary Embolism- Pre-clinical Phase Drug Overview
7.3 Pulmonary Embolism- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Pulmonary Embolism- Disease Overview
2.2 Pulmonary Embolism- Pipeline Snapshot
2.3 Pulmonary Embolism- Pipeline Drugs by Phase
2.4 Pulmonary Embolism- Pipeline Drugs by Company
2.5 Pulmonary Embolism- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Daiichi Sankyo Co Ltd Pulmonary Embolism Drug Pipeline, H2- 2019
3.2 Dong-A Socio Holdings Pulmonary Embolism Drug Pipeline, H2- 2019
3.3 Tasly Pharmaceutical Group Co Ltd Pulmonary Embolism Drug Pipeline, H2- 2019
3.4 TeaRx Ltd. Pulmonary Embolism Drug Pipeline, H2- 2019
3.5 Verseon Corp Pulmonary Embolism Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Pulmonary Embolism- Phase 1 Drug Details
4.2 Pulmonary Embolism- Phase 1 Drug Overview
4.3 Pulmonary Embolism- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Pulmonary Embolism- Phase 2 Drug Details
5.2 Pulmonary Embolism- Phase 2 Drug Overview
5.3 Pulmonary Embolism- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Pulmonary Embolism- Phase 3 Drug Details
6.2 Pulmonary Embolism- Phase 3 Drug Overview
6.3 Pulmonary Embolism- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Pulmonary Embolism- Pre-clinical Phase Drug Details
7.2 Pulmonary Embolism- Pre-clinical Phase Drug Overview
7.3 Pulmonary Embolism- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
